Novo Holdings considers sale of Xellia Pharmaceuticals

Novo Nordisk Foundation's investment company is examining opportunities for the sale of Xellia Pharmaceuticals.
Photo: Xellia Pharmaceuticals PR
Photo: Xellia Pharmaceuticals PR
BY MARKETWIRE, TRANSLATED BY CATHERINE BRETT

Sources have told Bloomberg News that Novo Holdings is currently investigating its options for a possible sale of Xellia Pharmaceuticals, which is headquartered in Amager, Copenhagen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading